Canaccord Genuity Upgrades Atara Biotherapeutics to Buy, Raises Price Target to $13

Benzinga Newsdesk www.benzinga.com Positive 88.2%

Neg 0% Neu 0% Pos 88.2%

Canaccord Genuity analyst John Newman upgrades Atara Biotherapeutics (NASDAQ:ATRA) from Hold to Buy and raises the price target from $6 to $13.